Arcus Biosciences (RCUS) Q3 2026 Earnings
How Did RCUS Stock React to Q3 2026 Earnings?
Did RCUS Beat Earnings? Q3 2026 Results
No. Arcus Biosciences reported Q3 2026 earnings of $-1.00 a share on Nov 4, 2026, missing the $-0.89 consensus estimate by 12.0%. Revenue was $9.0M against a $8.3M estimate.
Arcus Biosciences delivered a split verdict in the third quarter of 2026, beating on revenue while falling short on the bottom line, as the wind-down of its Gilead collaboration continued to reshape the company's financial profile. Revenue came in at $9.00 million, clearing the $8.27 million consensus by 8.83%, though it still represented a sharp 65.4% decline from a year earlier as collaboration reimbursements fell to $12.00 million from $28.00 million. On a GAAP basis, earnings per share landed at a loss of $1.00, missing the $0.89 consensus loss estimate by 12.04%, with the net loss narrowing modestly to $128.00 million from $135.00 million as total operating expenses declined to $140.00 million. The quarter's real story, however, was casdatifan, the HIF-2α inhibitor that management is positioning as a backbone therapy across every line of kidney cancer treatment, with investors eyeing a market opportunity the company has characterized at $5 billion to $10 billion. For the full year, Arcus guides GAAP revenue of $70.00 million to $75.00 million, and with $694.00 million in cash supplemented by $288.00 million in October equity proceeds, management projects a funding runway into 2029.
- Revenue decline driven by lower Gilead Collaboration revenue as activities wind down or reach completion
- Revenue decline partially offset by higher Taiho Collaboration Agreement revenue
- R&D expenses fell on wind-down of domvanalimab Phase 2/3 studies and completed PRISM-1 enrollment
- R&D savings partially offset by increased casdatifan Phase 3 activity
- Partnership reimbursements decreased ($12M vs $28M) due to shift toward fully self-funded programs
- G&A decreased due to streamlining initiatives
“In October, we showed for the first time that robust and durable HIF-2α inhibition from casdatifan can address the needs of patients at every line of kidney cancer therapy: rapid and sustained disease control in the first line, durable benefit and potential survival advantage in the second line, even after a prior TKI-inclusive therapy, and nearly three years of median overall survival in late-line patients who had exhausted multiple therapies.”
Arcus Biosciences CEO, on the earnings call
What Is Arcus Biosciences's Outlook?
Revenue and spending: - Arcus expects full-year 2026 GAAP revenue of $70 million to $75 million. - R&D expenses are expected to remain relatively consistent in the near term, as casdatifan and immunology investment offsets declines in other programs. - Cash of $694 million at quarter end plus $288 million in gross October equity proceeds is expected to fund operations into 2029. Near-term milestones: - PEAK-1 enrollment is expected to complete in two to three months. - PEAK-20 is expected to initiate in Q4 2026. - Bispecific combination cohorts and a randomized casdatifan-plus-tivozanib late-line cohort are expected to begin by year-end. - The PRISM-1 interim analysis is expected in Q4 2026. 2027 milestones: - A first-line anti-PD-1 plus axitinib cohort is planned for 1H 2027 to support PEAK-21. - More mature ARC-20 PFS and OS data are expected. - Immunology candidates are expected to enter the clinic or reach IND-ready status.
RCUS YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $9.0M | $26.0M | −65.4% |
| Operating Income | −$131.0M | −$121.6M | +7.7% |
| Net Income | −$128.0M | −$121.7M | +5.2% |
RCUS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.